XML 32 R18.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Stockholders' Equity | 12 Months Ended
--- | ---
Dec. 31, 2017
Stockholders' Equity Note [Abstract] |
Stockholders' Equity | Stockholders’ Equity Preferred Stock
|  |  |  |  | Shares Outstanding as of December 31,
| Shares Authorized |  | Shares Issued |  | 2017 |  | 2016
Series C Preferred Stock, par $0.001 | 1,091 |  |  | 1,091 |  |  | 23 |  |  | 23 |
The shares of the Company’s Series C Preferred Stock have the following pertinent rights and privileges, as set forth in the Company’s Amended and Restated Certificate of Incorporation and its Certificates of Designations, Rights and Preferences related to the various series of preferred stock. Rights on Liquidation In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company (a “liquidation event”), before any distribution of assets of the Company shall be made to or set apart for the holders of common stock, the holders of Series C Preferred Stock, pari passu, are entitled to receive payment of such assets of the Company in an amount equal to $10,000 per share of such series of preferred stock, plus any accumulated and unpaid dividends thereon (whether or not earned or declared). If the assets of the Company available for distribution to stockholders exceed the aggregate amount of the liquidation preferences payable with respect to all shares of each series of preferred stock then outstanding, then, after the payment of such preferences is made or irrevocably set aside, the holders of the Company’s common stock are entitled to receive a pro rata portion of such assets based on the aggregate number of shares of common stock held by each such holder. The holders of the Company’s outstanding preferred stock shall participate in such a distribution on a pro-rata basis, computed based on the number of shares of common stock which would be held by such preferred holders if immediately prior to the liquidation event all of the outstanding shares of the preferred stock had been converted into shares of common stock at the then current conversion value applicable to each series. A Change of Control of the Company (as defined in the Certificates of Designations, Rights and Preferences) is not a liquidation event triggering the preferences described above, and is instead addressed by separate terms in the Series C Certificates of Designations, Rights, and Preferences. Although the liquidation preferences are in excess of the par value of $0.001 per share of the Company’s preferred stock, these preferences are equal to or less than the stated value of such shares based on their original purchase price. Voting Rights The holders of Series C Preferred Stock have full voting rights and powers equal to the voting rights and powers of holders of the Company’s common stock and are entitled to notice of any stockholders’ meeting in accordance with the Company’s Bylaws. Holders are entitled to vote on any matter upon which holders of the Company’s common stock have the right to vote, including, without limitation, the right to vote for the election of directors together with the holders of common stock as one class. Series C Preferred holders are entitled to 368 votes for each share of Series C Preferred Stock held. Holder Optional Conversion Right The holder of any share or shares of Series C Preferred Stock has the right at any time, at such holder’s option, to convert all or any lesser portion of such holder’s shares of the Preferred Stock into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing (i) the aggregate Liquidation Preference applicable to the particular series of preferred shares, plus accrued and unpaid dividends thereon by (ii) the applicable Conversion Value (as defined in the relevant series’ Certificate of Designations, Rights and Preferences) then in effect for such series of preferred shares. As of December 31, 2017, the Conversion Value was $27.20, such that the outstanding shares of Series C Preferred Stock were convertible into 8,456 shares of common stock. The Company is not obligated to issue any fractional shares or scrip representing fractional shares upon such conversion and instead shall pay the holder an amount in cash equal to such fraction multiplied by the current market price per share of the Company’s common stock. Company Mandatory Conversion Option The Company has the option upon thirty (30) days prior written notice, to convert all of the outstanding shares of the Series C Preferred Stock into such number of fully paid and non-assessable shares of common stock as is determined by dividing (i) the aggregate Liquidation Preference of the shares of the relevant series of preferred stock to be converted, plus accrued and unpaid dividends thereon by (ii) the applicable Conversion Value (as defined in the relevant series’ Certificate of Designations, Rights and Preferences) then in effect, if the following triggering events have occurred: (i) the price of the Company’s common stock exceeds $72.00 per share for 20 out of 30 consecutive trading days; and (ii) the average daily trading volume (subject to adjustment for stock dividends, subdivisions and combinations) of the common stock exceeds 6,250 shares for at least 20 out of 30 consecutive trading days. Common Stock On July 25, 2017, the Company closed an underwritten public offering of 12,500,000 shares of common stock at a public offering price of $6.00 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $70.1 million. In June 2016, the Company entered into an At-the-Market Equity Offering Sales Agreement (the “Sales Agreement”) with an outside placement agent (the “Placement Agent”) to sell shares of its common stock with aggregate gross proceeds of up to $50.0 million, from time to time, through an “at-the-market” equity offering program under which the Placement Agent will act as sales agent. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The Sales Agreement provides that the Placement Agent will be entitled to compensation for its services in an amount equal to 2.0% of the gross proceeds from the sales of shares sold through the Placement Agent under the Sales Agreement. The Company has no obligation to sell any shares under the Sales Agreement, and may at any time suspend solicitation and offers under the Sales Agreement. During the year ended December 31, 2017, the Company sold a total of 2,937,406 shares of common stock under the Sales Agreement. The sales were made at a weighted average price of $8.41 per share with net proceeds to the Company of $24.2 million. As of December 31, 2017, the Company has sold an aggregate of 3,596,154 shares of common stock under the Sales Agreement for net proceeds of $30.5 million. Accordingly, as of December 31, 2017 the Company may sell up to an additional $18.9 million in shares of its common stock under the Sales Agreement. Warrants The Company accounts for registered common stock warrants issued in March 2013 under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock, on the understanding that in compliance with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies registered warrants on the consolidated balance sheet as a current liability which is revalued at each balance sheet date subsequent to the initial issuance. Determining the appropriate fair-value model and calculating the fair value of registered warrants requires some judgment, including estimating stock price volatility and expected warrant life. The Company develops its estimates based on historical data. A small change in the estimates used may have a relatively large change in the estimated valuation. The Company uses the Black-Scholes pricing model to value the registered warrants. Changes in the fair market value of the warrants are reflected in the consolidated statement of operations as “Change in fair value of common stock warrants". The following table summarizes the warrants outstanding as of December 31, 2017 and 2016:
|  |  |  |  |  | As of December 31, 2017 |  | As of December 31, 2016
Issued in Connection With: |  | Exercise Price |  | Expiration Date |  | Number of Warrants |  | Common Stock Warrant Liability |  | Number of Warrants |  | Common Stock Warrant Liability
March 2013 financing |  | $ | 3.17 |  |  | September 12, 2018 |  | 284,091 |  |  | $ | 360,795 |  |  | 284,091 |  |  | $ | 1,167,614 |
Total |  |  |  |  |  | 284,091 |  |  | $ | 360,795 |  |  | 284,091 |  |  | $ | 1,167,614 |
During the years ended December 31, 2017 and 2016, no warrants to purchase shares of the Company's common stock which were issued in connection with the March 2013 financing were exercised. Stock Options and Restricted Stock Units The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards and restricted stock unit awards (“RSUs”) to employees, directors and consultants. The 2016 Incentive Plan was approved by the Company's stockholders on May 13, 2016. The maximum number of shares of the Company’s common stock available for issuance over the term of the 2016 Incentive Plan may not exceed 6,000,000 shares, provided that commencing with the first business day of each calendar year beginning January 1, 2018, such maximum number of shares shall be increased by 2,000,000 shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2018, the maximum number of shares to be issued was increased by 2,000,000. At December 31, 2017, there were 6,000,000 shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At December 31, 2017, the Company had 3,994,511 shares of common stock available for future grant under the 2016 Incentive Plan, 819,507 shares underlying outstanding but unvested RSUs and options outstanding to purchase 1,136,057 shares of common stock under the 2016 Incentive Plan. The awards granted under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March 9, 2026. The Company’s previous stock-based incentive plan, the Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan"), was adopted on March 31, 2007 and terminated by its terms on March 31, 2017. At December 31, 2017, the Company had 414,661 shares underlying outstanding but unvested RSUs and options outstanding to purchase 6,357,071 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. At December 31, 2017, the Company also had options outstanding to purchase 201,742 shares of common stock under the VGX Equity Compensation Plan, which the Company assumed in connection with its acquisition of VGX in 2009. The terms and conditions of the options outstanding under this plan remain unchanged. Total stock-based compensation cost recognized in the consolidated statement of operations for the years ended December 31, 2017, 2016 and 2015 was $12.9 million, $10.2 million and $5.8 million, respectively, of which $5.8 million, $4.8 million and $3.2 million was included in research and development expenses and $7.1 million, $5.4 million and $2.6 million was included in general and administrative expenses, respectively. At December 31, 2017 and 2016, there was $5.9 million and $5.8 million of total unrecognized compensation cost, respectively, related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.8 years and 1.9 years respectively. At December 31, 2017 and 2016, there was $5.3 million and $4.0 million of total unrecognized compensation cost, respectively, related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.8 years and 2.0 years, respectively. The fair value of options granted to non-employees at the measurement dates were estimated using the Black-Scholes pricing model. Total stock-based compensation for options granted to non-employees for the years ended December 31, 2017, 2016 and 2015 was $201,000, $321,000 and $385,000, respectively. As of December 31, 2017, options to purchase 701,367 shares of common stock granted to non-employees remained outstanding. The following table summarizes total stock options outstanding at December 31, 2017:
|  | Options Outstanding |  | Options Exercisable
Exercise Price |  | Shares Underlying Options Outstanding |  | Weighted-Average Remaining Contractual Life (in Years) |  | Weighted Average Exercise Price |  | Shares Underlying Options Exercisable |  | Weighted Average Exercise Price
$1.48-$3.00 |  | 1,177,183 |  |  | 4.6 |  | $ | 2.25 |  |  | 1,177,183 |  |  | $ | 2.25 |
$3.01-$6.00 |  | 753,932 |  |  | 3.4 |  | $ | 4.64 |  |  | 668,244 |  |  | $ | 4.57 |
$6.01-$9.00 |  | 4,709,442 |  |  | 7.6 |  | $ | 7.09 |  |  | 2,639,454 |  |  | $ | 7.23 |
$9.01-$12.00 |  | 357,603 |  |  | 8.0 |  | $ | 9.79 |  |  | 263,180 |  |  | $ | 9.83 |
$12.01-$15.00 |  | 696,710 |  |  | 6.2 |  | $ | 12.96 |  |  | 696,710 |  |  | $ | 12.96 |
|  | 7,694,870 |  |  | 6.6 |  | $ | 6.77 |  |  | 5,444,771 |  |  | $ | 6.68 |
At December 31, 2017, the aggregate intrinsic value of options outstanding was $2.3 million, the aggregate intrinsic value of options exercisable was $2.3 million, and the weighted average remaining contractual term of options exercisable was 5.9 years. At December 31, 2017, the aggregate intrinsic value of unvested RSUs was $5.1 million and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2017 was $3.6 million. At December 31, 2017, options to purchase 7,694,870 shares of common stock and 1,234,168 RSUs are expected to vest. Stock option activity under the Company’s equity incentive plans during the year ended December 31, 2017 was as follows:
| Number of Shares |  | Weighted-Average Exercise Price
Balance, December 31, 2016 | 6,806,183 |  |  | $ | 6.81 |
Granted | 1,788,121 |  |  | 6.62 |
Exercised | (452,973 | ) |  | 5.18 |
Cancelled | (446,461 | ) |  | 8.49 |
Balance, December 31, 2017 | 7,694,870 |  |  | $ | 6.77 |
RSU activity under the Company’s equity incentive plans during the year ended December 31, 2017 was as follows:
| Number of Shares |  | Weighted-Average Exercise Price
Balance, December 31, 2016 | 798,834 |  |  | $ | — |
Granted | 1,035,443 |  |  | — |
Vested | (561,462 | ) |  | — |
Cancelled | (38,647 | ) |  | — |
Balance, December 31, 2017 | 1,234,168 |  |  | $ | — |
The weighted average exercise price per share was $9.67 for the 200,501 options which expired during the year ended December 31, 2017, $9.01 for the 69,570 options which expired during the year ended December 31, 2016 and $10.89 for the 83,696 options which expired during the year ended December 31, 2015. The weighted average grant date fair value per share was $4.33, $4.59 and $4.60 for options granted during the years ended December 31, 2017, 2016 and 2015, respectively. The weighted average grant date fair value was $6.66, $7.41 and $7.76 per share for RSUs granted during the years ended December 31, 2017, 2016 and 2015, respectively. The Company received $2.3 million, $1.8 million and $552,000 in proceeds from the exercise of stock options during the years ended December 31, 2017, 2016 and 2015, respectively. The aggregate intrinsic value of options exercised was $519,000, $3.5 million and $456,000 during the years ended December 31, 2017, 2016 and 2015, respectively.

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration